Acute Crit Care.  2023 Aug;38(3):333-342. 10.4266/acc.2023.00052.

Quality of life among patients with supraventricular tachycardia post radiofrequency cardiac ablation in Jordan

• Al- Betar MT

• KMID: 2547027
• DOI: http://doi.org/10.4266/acc.2023.00052

Abstract

Background
Supraventricular tachycardia (SVT) is a common arrhythmia with associated symptoms such as palpitation, dizziness, and fatigue. It significantly affects patients’ quality of life (QoL). Radiofrequency cardiac ablation (RFCA) is a highly effective treatment to eliminate arrhythmia and improve patients’ QoL. The purpose of this study was to assess the level of QoL among patients with SVT and examine the difference in QoL before and after RFCA.
Methods
One group pre-posttest design with a convenience sample of 112 patients was used. QoL was assessed by 36-Item Short Form (SF-36). Data were collected at admission through face-to-face interviews and 1-month post-discharge through phone interviews.
Results
There was a significant difference between QoL before (33.7±17.0) and 1 month after (62.5±18.5) the RFCA. Post-RFCA patients diagnosed with atrioventricular nodal reentrant tachycardia had higher QoL than other types of SVT. Moreover, there were significant negative relationships between QoL and the number and duration of episodes pre- and post-RFCA. There were no significant differences in QoL based on: age, sex, working status, marital status, smoking, coronary artery disease, diabetes mellitus, and hypertension.
Conclusions
After RFCA, the QoL of patients with ST improved for both physical and mental component subscales.

Reference

1. Orejarena LA, Vidaillet H Jr, DeStefano F, Nordstrom DL, Vierkant RA, Smith PN, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998; 31:150–7.

2. Rehorn M, Sacks NC, Emden MR, Healey B, Preib MT, Cyr PL, et al. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol. 2021; 32:2199–206.

3. White J, Withers KL, Lencioni M, Carolan-Rees G, Wilkes AR, Wood KA, et al. Cardiff cardiac ablation patient-reported outcome measure (C-CAP): validation of a new questionnaire set for patients undergoing catheter ablation for cardiac arrhythmias in the UK. Qual Life Res. 2016; 25:1571–83.

4. Porter MJ, Morton JB, Denman R, Lin AC, Tierney S, Santucci PA, et al. Influence of age and gender on the mechanism of supraventricular tachycardia. Heart Rhythm. 2004; 1:393–6.

5. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomström-Lundqvist C, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020; 41:655–720.

6. Ernst S. Catheter ablation: general principles and advances. Card Electrophysiol Clin. 2017; 9:311–7.

7. Helton MR. Diagnosis and management of common types of supraventricular tachycardia. Am Fam Physician. 2015; 92:793–800.

8. Nieminen MS, Dickstein K, Fonseca C, Serrano JM, Parissis J, Fedele F, et al. The patient perspective: quality of life in advanced heart failure with frequent hospitalisations. Int J Cardiol. 2015; 191:256–64.

9. Abo-Haded HM. Radiofrequency ablation changes the quality of life of children with supraventricular tachycardias. Arch Dis Child. 2015; 100:754–7.

10. Al-Zaiti SS, Magdic KS. Paroxysmal supraventricular tachycardia: pathophysiology, diagnosis, and management. Crit Care Nurs Clin North Am. 2016; 28:309–16.

11. Katritsis DG, Josephson ME. Differential diagnosis of regular, narrow-QRS tachycardias. Heart Rhythm. 2015; 12:1667–76.

12. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995; 41:1403–9.

13. Farkowski MM, Pytkowski M, Maciag A, Golicki D, Wood KA, Kowalik I, et al. Gender-related differences in outcomes and resource utilization in patients undergoing radiofrequency ablation of supraventricular tachycardia: results from patients’ perspective on radiofrequency catheter ablation of AVRT and AVNRT Study. Europace. 2014; 16:1821–7.

14. Nordblom AK, Broström A, Fridlund B. Impact on a person’s daily life during episodes of supraventricular tachycardia. J Holist Nurs. 2017; 35:33–43.

15. Hayeah HM, Saifan AR, AbuRuz ME, Aljabery MA. Health-related quality of life in heart failure in Jordan from patient’s perspectives. IOSR J Nurs Health Sci. 2017; 6:14–21.

16. Domeyer PR, Giannakidou SC, Kyriakou P, Katsari V, Antoniadis AP, Lagos IK, et al. Impact of radiofrequency ablation and antiarrhythmic medications on the quality of life of patients with supraventricular tachycardias: preliminary validation of the Greek version of the Umea22 (U22) Questionnaire. Biomed Res Int. 2018; 2018:3059478.

17. Eitel C, Ince H, Brachmann J, Kuck KH, Willems S, Gerds-Li JH, et al. Atrial fibrillation ablation strategies and outcome in patients with heart failure: insights from the German ablation registry. Clin Res Cardiol. 2019; 108:815–23.

18. Papiashvili G, Tabagari-Bregvadze N, Brugada J. Influence of catheter ablation of paroxysmal supraventricular tachycardia on patients’ anxiety. Georgian Med News. 2018; 58–60.

19. Brachmann J, Lewalter T, Kuck KH, Andresen D, Willems S, Spitzer SG, et al. Long-term symptom improvement and patient satisfaction following catheter ablation of supraventricular tachycardia: insights from the German ablation registry. Eur Heart J. 2017; 38:1317–26.

20. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41:1149–60.

21. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30:473–83.

22. Ware JE Jr. SF-36 health survey update. Spine (Phila Pa 1976). 2000; 25:3130–9.

23. Guermazi M, Allouch C, Yahia M, Huissa TB, Ghorbel S, Damak J, et al. Translation in Arabic, adaptation and validation of the SF-36 Health Survey for use in Tunisia. Ann Phys Rehabil Med. 2012; 55:388–403.

24. Younsi M. Health-related quality-of-life measures: evidence from Tunisian population using the SF-12 Health Survey. Value Health Reg Issues. 2015; 7:54–66.

25. RAND Health Care. 36-Item short form survey (SF-36) scoring instructions: health-related quality of life. RAND; 2016.

26. Coons SJ, Alabdulmohsin SA, Draugalis JR, Hays RD. Reliability of an Arabic version of the RAND-36 Health Survey and its equivalence to the US-English version. Med Care. 1998; 36:428–32.

27. AbuRuz ME. Anxiety and depression predicted quality of life among patients with heart failure. J Multidiscip Healthc. 2018; 11:367–73.

28. Papiashvili G, Tabagari-Bregvadze N, Brugada J. Impact of radiofrequency catheter ablation on health-related quality of life assessed by the Sf-36 Questionnaire in patients with paroxysmal supraventricular tachycardia. Georgian Med News. 2018; 54–7.

29. Mueed A, Rathi N, Ashraf J, Ahmed S, Rai Ll. Quality of life after ablation vs medication therapy in patients with supraventricular tachycardia. J Pharm Res Int. 2021; 33:86–93.

30. Aljabery MA, Rajeh Saifan A, Alrimawi I, Alzoubi AM, Atout M. The associations between patients’ characteristics and the quality of life among acute coronary syndrome patients in Jordan: a cross-sectional study. SAGE Open Nurs. 2022; 8:23779608221129129.

31. Walfridsson U. Assessing symptom burden and health-related quality of life in patients living with arrhythmia and ASTA: arrhythmia-specific questionnaire in tachycardia and arrhythmia. Linköping University Electronic Press;2011.

32. El-Medany AY, Grubb NR. Supraventricular tachycardia and catheter ablation: anxiety levels and patient perceptions. Res Medica. 2014; 22:2–14.

33. Kesek M, Rönn F, Tollefsen T, Höglund N, Näslund U, Jensen SM. Symptomatic improvement after catheter ablation of supraventricular tachycardia measured by the arrhythmia-specific questionnaire U22. Ups J Med Sci. 2011; 116:52–9.

34. Holmqvist F, Kesek M, Englund A, Blomström-Lundqvist C, Karlsson LO, Kennebäck G, et al. A decade of catheter ablation of cardiac arrhythmias in Sweden: ablation practices and outcomes. Eur Heart J. 2019; 40:820–30.

35. Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, et al. 2015 ACC/AHA/HRS Guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016; 67:e27–115.

36. Wood KA, Stewart AL, Drew BJ, Scheinman MM, Froëlicher ES. Patient perception of symptoms and quality of life following ablation in patients with supraventricular tachycardia. Heart Lung. 2010; 39:12–20.

37. O’Hara GE, Philippon F, Champagne J, Blier L, Molin F, Côté JM, et al. Catheter ablation for cardiac arrhythmias: a 14-year experience with 5330 consecutive patients at the Quebec Heart Institute, Laval Hospital. Can J Cardiol. 2007; 23(Suppl B):67B–70B.

38. Park J, Wi J, Joung B, Lee MH, Kim YH, Hwang C, et al. Prevalence, risk, and benefits of radiofrequency catheter ablation at the aortic cusp for the treatment of mid- to anteroseptal supra-ventricular tachyarrhythmias. Int J Cardiol. 2013; 167:981–6.

39. Nakagawa H, Jackman WM. Catheter ablation of paroxysmal supraventricular tachycardia. Circulation. 2007; 116:2465–78.

40. Papiashvili G, Tabagari-Bregvadze N, Brugada J. Anxiety levels in patients with paroxy-smal supraventricular tachycardia in relation with the patient demographics, type of supraventricular tachycardia and their personality type. Georgian Med News. 2017; (267):61–5.